Judo Bio key facts
- Developer of oligonucleotide therapies intended to offer genetic medicines.
- Judo Bio’s last known valuation is $115.0M.
- It has raised $105.0M across 3 recorded rounds; the latest was Early Stage VC ($25.0M) in Jul 2024.
- Notable investors include Alexandria Venture Investments, Digitalis Ventures, Euclidean Capital, Atlas Venture, Droia Ventures — 7 tracked in total.
- Judo Bio has filed 4 Form Ds with the SEC since 2022, most recently Aug 2024 ($25.0M sold to 21 investors).
- Status: Privately Held (backing).
- ·Watch Judo Bio: the Monday email on marks, rounds and moves
Judo Bio funding rounds
3 roundsJudo Bio valuation
Judo Bio's last known valuation is $115 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
How much has Judo Bio raised?
Judo Bio has raised $105 million across 3 recorded rounds since 2022. The largest was a $5 million early-stage round in May 2024; the most recent was a $25 million early-stage round in Jul 2024.
Judo Bio has filed 4 Form Ds with the SEC since 2022, most recently in Aug 2024 ($25 million sold to 21 investors).
Judo Bio investors
7 investors are on record for Judo Bio, including Alexandria Venture Investments, Digitalis Ventures, Euclidean Capital and Atlas Venture. The early-stage round in Jul 2024 drew 21 investors.
About Judo Bio
Developer of oligonucleotide therapies intended to offer genetic medicines. The company helps to pair the gene-silencing nucleic acid with a targeting molecule to specific types of kidney cells, enabling healthcare professionals to treat systemic and renal diseases.
- Sector
- Healthcare
- HQ
- Cambridge, MA, United States
- Founded
- 2021
- Employees
- 4
- Website
- judo.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Judo Bio’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.